anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Premature Ventricular Complexes (PVCs) are very common in clinical practice, with frequent PVCs (more than 30 beats per hour) or polymorphic PVCs significantly increasing the risk of mortality. Previous studies have shown that vagus nerve stimulation improves ventricular arrhythmias. Stimulation of the auricular distribution of the vagus nerve has proven to be a simple, safe, and effective method to activate the vagus nerve. Transcutaneous au ricular vagus nerve stimulation (taVNS) has shown promise in both clinical and experimental setting for PVCs; however, high-quality clinical studies are lacking, resulting in insufficient evidence of efficacy.
METHODS: The study is a prospective, randomized, parallel-controlled trial with a 1:1 ratio between the two groups. Patients will be randomized to either the treatment group (taVNS) or the control group (Sham-taVNS) with a 6-week treatment and a subsequent 12-week follow-up period. The primary outcome is the proportion of patients with a ≥ 50% reduction in the number of PVCs monitored by 24-hour Holter. Secondary outcomes include the proportion of patients with a ≥ 75% reduction in PVCs, as well as the changes in premature ventricular beats, total heartbeats, and supraventricular premature beats recorded by 24-hour Holter. Additional assessments compared score changes in PVCs-related symptoms, as well as the score change of self-rating anxiety scale (SAS), self-rating depression scale (SDS), and 36-item short form health survey (SF-36).
DISCUSSION: The TASC-V trial will help to reveal the efficacy and safety of taVNS for frequent PVCs, offering new clinical evidence for the clinical practice.
TRIAL REGISTRATION: Clinicaltrials.gov: NCT04415203 (Registration Date: May 30, 2020).
Methods to determine the susceptibility of a subject to erythrocyte diseases are provided. The methods comprise determining the miRNA compositions of erythrocytes from the subject. The present invention has discovered that erythrocytes comprise microRNA (miRNA) populations and the populations can be profiled or analyzed and used to determine the susceptibility for disease. The miRNA compositions can also be used to determine the severity of erythrocyte disease, and the features and clinical phenotypes of the erythrocyte disorders. Also provided are pharmaceutical compositions comprising erythrocyte miRNAs and methods for the treatment of a subject with an erythrocyte disease. In other embodiments of the invention, the miRNAs can be used to increase the life-span of erythrocytes through the introduction of an erythrocyte miRNA.
OBJECTIVE: Complex diseases exhibit heterogeneous progression patterns, necessitating effective capture and clustering of longitudinal changes to identify disease subtypes for personalized treatments. However, existing studies often fail to design clustering-specific representations or neglect clinical outcomes, thereby limiting the interpretability and clinical utility.
METHOD: We design a unified framework for subtyping longitudinal progressive diseases. We focus on effectively integrating all data from disease progressions and improving patient representation for downstream clustering. Specifically, we propose a clinical Outcome-Guided Deep Temporal Clustering (OG-DTC) that generates representations informed by clustering and clinical outcomes. A GRU-based seq2seq architecture captures the temporal dynamics, and the model integrates k-means clustering and outcome regression to facilitate the formation of clustering structures and the integration of clinical outcomes. The learned representations are clustered using a Gaussian mixture model to identify distinct subtypes. The clustering results are extensively validated through reproducibility, stability, and significance tests.
RESULTS: We demonstrated the efficacy of our framework by applying it to three Alzheimer's Disease (AD) clinical trials. Through the AD case study, we identified three distinct subtypes with unique patterns associated with differentiated clinical declines across multiple measures. The ablation study revealed the contributions of each component in the model and showed that jointly optimizing the full model improved patient representations for clustering. Extensive validations showed that the derived clustering is reproducible, stable, and significant.
CONCLUSION: Our temporal clustering framework can derive robust clustering applicable for subtyping longitudinal progressive diseases and has the potential to account for subtype variability in clinical outcomes.
25 cases each of fasciotomy will be closed either by dermotaxis or loop suture technique with the inclusion criteria being closed fractures, no concomitant skin loss, fracture related compartment syndrome and fasciotomy within 36 hrs. The fasciotomy incision will be either closed in a single stage by loop suture technique or gradually by dermotaxis once the edema settled between 3-5 days. The results will be graded as excellent if approximation could be achieved, good if sutures have to be applied for protective care and poor if they have to be grafted. In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.

The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
The present invention relates to a method of identifying one or more T cells, as well as method of isolating one or more T cells. Further, the invention relates to a method of identifying one or more TCR, a nucleic acid molecule comprising a nucleic acid sequence encoding the TCR identified by the methods of the invention. The invention also relates to a method of generating one or more immune cells. The invention also relates to a host cell comprising a nucleic molecule encoding a TCR identified by the invention or generated by a method of the invention. The invention also relates to a pharmaceutical composition comprising a cell of the invention, or a cell of the invention for use in therapy. Finally, the invention also relates to a method of diagnosing cancer.
Stroke Patients: A stroke occurs when a clot (or thrombus) forms in a blood vessel in the brain or forms in another part of the body and breaks off, then travels to the brain (an embolus). In both cases the blood supply to part of the brain is blocked and that part of the brain is damaged. Ticlopidine hydrochloride tablets work by making the blood less likely to clot, although not so much less that it causes you to become likely to bleed, unless you have a bleeding disorder or some injury (such as a bleeding ulcer of the stomach or intestine) that is especially likely to bleed.

Stent Patients: A heart attack or angina (chest pain) can occur when fatty deposits block the arteries that carry oxygen and nutrient-rich blood to your heart. To decrease the chance of fatty deposits building up over time, your doctor may recommend the placement of a coronary stent. Ticlopidine hydrochloride tablets may be given to you with aspirin to make blood clots less likely to form inside the stent so that the artery remains open.
The invention relates to a traditional Chinese medicine acupoint plaster formula for preventing and treating myopia, a preparation method and a using method thereof. The plaster comprises the following components: fructus Lycii, concha Haliotidis, alismatis rhizoma, caulis Spatholobi, fossilia Spiriferis, notoginseng radix, arillus longan, moschus, and Borneolum Syntheticum. 15-20 parts of each of artificial musk and borneol. The acupoint plaster of the invention adopts the mixture of 30 to 40 parts of camellia oil and 10 to 20 parts of peppermint oil as the matrix of the Chinese medicinal plaster according to the theory of traditional Chinese medicine and the principle of transdermal absorption of medicaments. The plaster of the invention is directly applied to Jingming, zanzhu, tongziliao, yangbai and Sibai acupoints around eyes of patients, and then is applied to acupuncture and moxibustion patch for more than 24 hours, thereby recovering asthenopia, improving the eye muscle regulating ability, treating pseudomyopia and improving eyesight. The prevention and treatment effect is obvious, the period is short, and rebound is avoided. Prevention and treatment are more important for early treatment and early rehabilitation. The invention is economic, effective, simple, practical, green and safe.
Advise the patient to read the FDA-approved patient labeling (Patient Information). 

Lactic Acidosis: Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development. Advise patients to discontinue metformin hydrochloride tablets immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur. Counsel patients against excessive alcohol intake and inform patients about importance of regular testing of renal function while receiving metformin hydrochloride tablets. Instruct patients to inform their doctor that they are taking metformin hydrochloride tablets prior to any surgical or radiological procedure, as temporary discontinuation may be required [see Warnings and Precautions (5.1)]. 

Hypoglycemia: Inform patients that hypoglycemia may occur when metformin hydrochloride tablets are coadministered with oral sulfonylureas and insulin. Explain to patients receiving concomitant therapy the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development [see Warnings and Precautions (5.3)].

Vitamin B12 Deficiency: Inform patients about importance of regular hematological parameters while receiving metformin hydrochloride tablets [see Warnings and Precautions (5.2)]. 

Females of Reproductive Age: Inform females that treatment with metformin hydrochloride tablets may result in ovulation in some premenopausal anovulatory women which may lead to unintended pregnancy [see Use in Specific Populations (8.3)].
The invention discloses a vaccine composition for resisting beta coronavirus and application thereof, belonging to the technical field of biology. The vaccine composition for resisting the beta coronavirus is inoculated through a mucosal route and comprises novel coronavirus nucleocapsid protein, phosphodiester backbone CpG oligodeoxynucleotide and pharmaceutic adjuvants. Meanwhile, the invention also relates to the application of the vaccine composition in the production of a medicine for resisting the novel coronavirus. And further provides methods of vaccinating the compositions to induce both humoral and cell-mediated immune responses against the beta coronavirus. By vaccination via the mucosal route, particularly after intranasal administration, cell-mediated immune cross-responses against N protein can be induced, and cross-antibodies against N protein can be induced, in a modulated Th1 immune response pattern. Meanwhile, the vaccine composition preparation has potential safety.
Group P will receive a stat dose of IV palonosetron 1.5mcg/kg diluted in a 5ml preparation of normal saline 0.9% prior to the commencement of general anaesthesia. At the start of wound closure, Group P will receive a 5ml preparation of normal saline 0.9% as a placebo.
Hemolytic peptides are therapeutic peptides that damage red blood cells. However, therapeutic peptides used in medical treatment must exhibit low toxicity to red blood cells to achieve the desired therapeutic effect. Therefore, accurate prediction of the hemolytic activity of therapeutic peptides is essential for the development of peptide therapies. In this study, a multi-feature cross-fusion model, HemoFuse, for hemolytic peptide identification is proposed. The feature vectors of peptide sequences are transformed by word embedding technique and four hand-crafted feature extraction methods. We apply multi-head cross-attention mechanism to hemolytic peptide identification for the first time. It captures the interaction between word embedding features and hand-crafted features by calculating the attention of all positions in them, so that multiple features can be deeply fused. Moreover, we visualize the features obtained by this module to enhance its interpretability. On the comprehensive integrated dataset, HemoFuse achieves ideal results, with ACC, SP, SN, MCC, F1, AUC, and AP of 0.7575, 0.8814, 0.5793, 0.4909, 0.6620, 0.8387, and 0.7118, respectively. Compared with HemoDL proposed by Yang et al., it is 3.32%, 3.89%, 5.93%, 10.6%, 8.17%, 5.88%, and 2.72% higher. Other ablation experiments also prove that our model is reasonable and efficient. The codes and datasets are accessible at https://github.com/z11code/Hemo .
The invention provides spleen regulation type B lymphocytes and a preparation method and application thereof. The invention provides spleen regulatory B lymphocytes, wherein the proportion of the CD1d, CD5 and CD21/35 antibody positive regulatory B lymphocytes in the cells is more than 94.6%. In a second aspect, the present invention provides a method for preparing spleen-regulated B lymphocytes. The method for preparing spleen regulatory B lymphocytes comprises the following steps: taking spleen cell suspension, and marking the spleen cell suspension by using surface antibodies CD1d, CD5 and CD 21/35; fluorescence activated cell sorting labeled cells. The third aspect of the invention provides application of the spleen-regulating B lymphocytes in preparation of a preparation for targeted engraftment on bilateral kidneys. The fourth aspect of the invention provides application of the spleen regulatory B lymphocytes in preparing products for kidney protection.
NEW MATERIAL:A compound expressed by formula I [R is OH, NH2 or OR' (R' is 1-5C alkyl); X is H or OH]. EXAMPLE:Acryloyl-D-proline methyl ester. USE:A compound readily convertible into polymers having stimulation responsiveness function. Since the polymers have a great extent of swelling and shrinking in water and function to respond to microstimulation, such as solvent or temperature, and completely recover to the original swollen or shrunk state in removing the microstimulation, the scope of utilization is extremely wide. For example, the polymers can be used for mixing a physiologically active substance therein and controlling the sustained release properties thereof with the stimulation responsiveness function, etc. PREPARATION:An active ester of acrylic acid, such as acrylic acid chloride, is reacted with a proline derivative expressed by formula II (e.g., proline methyl ester) in a solvent, e.g., dioxan, to afford the compound expressed by formula I.
BACKGROUND: The prognosis of HCC patients without MVI (so called M0) is highly heterogeneous and the need for adjuvant therapy is still controversial.
METHODS: Patients with HCC with M0 who underwent liver resection (LR) or liver transplantation (LT) as an initial therapy were included. The Eastern Hepatobiliary Surgery Hospital (EHBH)-M0 score was developed from a retrospective cohort to form the training cohort. The classification which was developed using multivariate cox regression analysis was externally validated.
RESULTS: The score was developed using the following factors: α-fetoprotein level, tumour diameter, liver cirrhosis, total bilirubin, albumin and aspartate aminotransferase. The score differentiated two groups of M0 patients (≤3, >3 points) with distinct long-term prognoses outcomes (median overall survival (OS), 98.0 vs. 46.0 months; p < 0.001). The predictive accuracy of the score was greater than the other commonly used staging systems for HCC. And for M0 patients with a higher score underwent LR. Adjuvant transcatheter arterial chemoembolization (TACE) was effective to prolong OS.
CONCLUSIONS: The EHBH M0 scoring system was more accurate in predicting the prognosis of HCC patients with M0 after LR or LT. Adjuvant therapy is recommended for HCC patients who have a higher score.
Improved systems and devices for pre-caching of related medical imaging are provided. A medical imaging order may be received from a medical facility that includes medical imaging of a site generated by a medical imaging device. The medical imaging order may include metadata, such as user data, site data, and modality data. A search may be executed for supplemental medical imaging of the user using the user data. The supplemental medical imaging may be filtered using the site data to return only that medical imaging related to the site. The filtered supplemental medical imaging may be prioritized using the modality data. The prioritized supplemental medical imaging may be appended to the request, and the request may be transmitted to a radiologist for generation of a medical imaging report.
Epoxyeicosatrienoic acids (EETs) and other epoxy fatty acids are short-acting lipids involved in resolution of inflammation. Their short half-life, due to its metabolism by soluble epoxide hydrolase (sEH), limits their effects. Specialized proresolving mediators (SPMs) are endogenous regulatory lipids insufficiently synthesized in uncontrolled and chronic inflammation. Using an experimental periodontitis model, we pharmacologically inhibited sEH, examining its impact on T cell activation and systemic SPM production. In humans, we analyzed sEH in the gingival tissue of periodontitis patients. Mice were treated with sEH inhibitor (sEHi) and/or EETs before ligature placement and treated for 14 d. Bone parameters were assessed by microcomputed tomography and methylene blue staining. Blood plasma metabololipidomics were carried out to quantify SPM levels. We also determined T cell activation by reverse transcription-quantitative PCR and flow cytometry in cervical lymph nodes. Human gingival samples were collected to analyze sEH using ELISA and electrophoresis. Data reveal that pharmacological sEHi abrogated bone resorption and preserved bone architecture. Metabololipidomics revealed that sEHi enhances lipoxin A4, lipoxin B4, resolvin E2, and resolvin D6. An increased percentage of regulatory T cells over Th17 was noted in sEHi-treated mice. Lastly, inflamed human gingival tissues presented higher levels and expression of sEH than did healthy gingivae, being positively correlated with periodontitis severity. Our findings indicate that sEHi preserves bone architecture and stimulates SPM production, associated with regulatory actions on T cells favoring resolution of inflammation. Because sEH is enhanced in human gingivae from patients with periodontitis and connected with disease severity, inhibition may prove to be an attractive target for managing osteolytic inflammatory diseases.
Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 1 week prior to beginning therapy. CellCept therapy should not be initiated until a negative pregnancy test report is obtained. 

Women of childbearing potential (including pubertal girls and peri-menopausal women) taking CellCept must receive contraceptive counseling and use effective contraception. The patient should begin using her two chosen methods of contraception 4 weeks prior to starting CellCept therapy, unless abstinence is the chosen method. She should continue contraceptive use during therapy and for 6 weeks after stopping CellCept. Patients should be aware that CellCept reduces blood levels of the hormones in the oral contraceptive pill and could theoretically reduce its effectiveness (see  PRECAUTIONS: Information for Patients  and PRECAUTIONS: Drug Interactions: Oral Contraceptives).
First part of two part treatment, Part One: three 3-week cycles 300 mg of ZD6474 daily. Second part, Part Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m\^2 IV over 3 hours on Day 1 every 3 weeks.
The present invention relates to a therapeutic herbal composition comprising of a novel combination of the phytochemicals namely curcuminoids and carotenoids such as lutein. More particularly the therapeutic herbal composition comprises of Curcuminoids and Lutein along with the excipients wherein the curcuminoids are present in the range of 24- 49%, lutein is present in the range of 1%-14.5% and the excipients are in the range of 50-64%. The said therapeutic herbal composition is effective in regulating blood lipid profile, in modulating the inflammatory effects and having anti-inflammatory effects. Additionally, the said therapeutic herbal composition is effective in management of diseases caused due to factors such as inflammation, oxidative stress etc. and diseases such as Diabetic Retinopathy and Age Related Macular Degeneration. Also provided is a novel process for manufacturing such a composition and its use in foods, beverages including alcoholic beverages and as nutraceutical products, dietary supplements and pharmaceuticals.
The colon capsule comprises two cameras located at both ends. Image acquisition is set between four to thirty-five images per second. It begins immediately after ingestion of the capsule which allows recording of esophageal and gastric images. She paused for 2 hours (to save batteries) while crossing the small intestine. It is reactivated in the terminal ileum. The films analysis time is approximately 1 hour, and the capsule remains on average 3 hours in the colon.
FIELD: pulmonary diseases. SUBSTANCE: invention aims at affecting primarily shock organ, increasing lymph circulation in it, and increasing reabsorption of high-molecular protein compounds from interstitial space of lungs. In this case, electrolytic balance is not disturbed, danger of acute decrease of arterial tension no more exists, and rheological properties of blood and lymph are improved. Such result is achieved by inserting proteolytic enzyme terrodecase in quantity 10-20 proteolytic units under swordlike appendix of thorax into tissue of overdiaphragme space. Method may be used in reanimation and intensive therapy departments in various therapeutic enterprises. EFFECT: improved therapeutic effect.